文献速递免疫规划传染病防控与疫情报告

无血清Vero细胞培养生产的重组水疱性口炎病毒载体HIV疫苗候选株评价

Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.
PubMed 文献 · Vaccine · 2020-11-01

研究设计并生产了三种以重组水疱性口炎病毒(rVSV)为载体的新型HIV疫苗候选株,在Vero细胞中小规模评估生产动力学,纯化后符合WHO残留DNA和宿主细胞蛋白限制,小鼠给药后均诱导HIV gp140特异性抗体应答。

要点

  • 三种rVSV-HIV疫苗候选株在Vero细胞中的生产动力学随所用HIV gp表面蛋白不同而变化。
  • 纯化病毒制备符合WHO对残留DNA和宿主细胞蛋白含量的限制。
  • 三种候选疫苗在小鼠中均诱导HIV gp140特异性抗体应答。

核心结论

  • 三种新型rVSV载体HIV疫苗候选株可在Vero细胞中生产,纯化后符合WHO残留杂质限制,并在小鼠中诱导HIV gp140特异性抗体应答。

研究设计与样本

  • 研究设计、拯救、生产和纯化三种rVSV-HIV疫苗候选株(rVSV-B6-NL4.3Env/SIVtm、rVSV-B6-NL4.3Env/Ebtm和rVSV-B6-A74Env(PN6)/SIVtm),在Vero细胞中小规模评估生产,并在小鼠中评价免疫原性。

主要发现

  • 三种候选疫苗在Vero细胞上的生产动力学随所用HIV gp表面蛋白不同而变化。
  • 纯化病毒制备符合WHO对残留DNA和宿主细胞蛋白含量的限制。
  • 三种rVSV-HIV疫苗候选株在小鼠中均诱导HIV gp140特异性抗体应答。

局限性

  • 免疫原性评价仅在小鼠中进行,尚未在非人灵长类开展临床前研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired Immune Deficiency Syndrome (AIDS) in humans is a result of the destruction of the immune system caused by Human Immunodeficiency Virus (HIV) infection. This serious epidemic is still progressing world-wide. Despite advances in treatment, a safe and effective preventive HIV vaccine is desired to combat this disease, and to save millions of lives. However, such a vaccine is not available yet although extensive amounts of resources in research and development have been invested over three decades. In light of the recently approved Ebola virus disease vaccine based on a recombinant vesicular stomatitis virus (rVSV-ZEBOV), we present the results of our work on three novel VSV-vectored HIV vaccine candidates. We describe the design, rescue, production and purification method and evaluate their immunogenicity in mice prior to preclinical studies that will be performed in non-human primates. The production of each of the three candidate vaccines (rVSV-B6-NL4.3Env/SIVtm, rVSV-B6-NL4.3Env/Ebtm and rVSV-B6-A74Env(PN6)/SIVtm) was evaluated in small scale in Vero cells and it was found that production kinetics on Vero cells vary depending on the HIV gp surface protein used. Purified virus preparations complied with the WHO restrictions for the residual DNA and host cell protein contents. Finally, when administered to mice, all three rVSV-HIV vaccine candidates induced an HIV gp140-specific antibody response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mangion M, Gélinas JF, Bakhshi Zadeh Gashti A, et al. Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. Vaccine. 2020. PMID: 33139138. doi:10.1016/j.vaccine.2020.10.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。